Pluri Inc.
A biotechnology company in Haifa, Israel, that grows human, animal, and plant cells at industrial scale using a three-dimensional cell-expansion platform. Its placenta-derived PLX cell therapies target inflammatory and muscle conditions, while the same technology also feeds cultivated-meat and agricultural projects. Founded from stem-cell patents developed during founder Shai Meretzki's PhD at the Technion, it was long known as Pluristem Therapeutics before shortening its name to Pluri in 2022 — a nod to "pluripotent" cells.
Item 4 of the Schedule 13D is hereby amended and restated as follows: The information contained on the cover pages of this Schedule 13D relating to CHL, CHLP, Plantae and Mr. Weinstein is incorporated by reference.
Item 4 of the Schedule 13D is hereby amended and restated as follows: The information contained on the cover pages of this Schedule 13D relating to CHL, CHLP, Plantae and Mr. Weinstein is incorporated by reference.
Item 4 of the Schedule 13D is hereby amended and restated as follows: The information contained on the cover pages of this Schedule 13D relating to CHL, CHLP, Plantae and Mr. Weinstein is incorporated by reference.
Item 4 of the Schedule 13D is hereby amended and restated as follows: The information contained on the cover pages of this Schedule 13D relating to CHL, CHLP, Plantae and Mr. Weinstein is incorporated by reference.
"Item 4. Purpose of Transaction" is being amended and restated by this Amendment No. 1 as follows: All of the Issuer's securities directly owned by the Reporting Person was acquired for investment purposes and in consideration for the Reporting Person's services as a former executive officer of the Issuer. In pursuing these purposes, the Reporting Person may further purchase, hold, trade, dispose or otherwise deal in securities of the Issuer. Except as set forth in the previous paragraph, the Reporting Person has no current plans or proposals which relate to or would result in (a) an acquisition by any person of additional securities of the Issuer, or the disposition by any person of securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or of any of its subsidiaries; (d) any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions with may impede the acquisition of control of the Issuer by any person; (h) causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or (j) any action similar to any of those enumerated herein. The Reporting Person may, at any time and from time to time, review or reconsider her position and formulate plans or proposals with respect thereto.
"Item 4. Purpose of Transaction" is being amended and restated by this Amendment No. 1 as follows: All of the Issuer's securities directly and beneficially owned by the Reporting Person were acquired for investment purposes and in consideration for the Reporting Person's services as an executive officer and Director of the Issuer. In pursuing these purposes, the Reporting Person may further purchase, hold, trade, dispose or otherwise deal in securities of the Issuer. The Reporting Person has no current plans or proposals which relate to or would result in (a) an acquisition by any person of additional securities of the Issuer, or the disposition by any person of securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or of any of its subsidiaries; (d) any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions with may impede the acquisition of control of the Issuer by any person; (h) causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or (j) any action similar to any of those enumerated herein. The Reporting Person may, at any time and from time to time, review or reconsider his position and formulate plans or proposals with respect thereto.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Alexandre Weinstein | 13D/AActivist | 35% | 4.35M | Jul 1, 2026 |
Item 4 of the Schedule 13D is hereby amended and restated as follows: The information contained on the cover pages of this Schedule 13D relating to CHL, CHLP, Plantae and Mr. Weinstein is incorporated by reference. | ||||
| Chutzpah Holdings Ltd | 13D/AActivist | 18.5% | 2.02M | Jul 1, 2026 |
Item 4 of the Schedule 13D is hereby amended and restated as follows: The information contained on the cover pages of this Schedule 13D relating to CHL, CHLP, Plantae and Mr. Weinstein is incorporated by reference. | ||||
| Chutzpah Holdings LP | 13D/AActivist | 16.37% | 1.88M | Jul 1, 2026 |
Item 4 of the Schedule 13D is hereby amended and restated as follows: The information contained on the cover pages of this Schedule 13D relating to CHL, CHLP, Plantae and Mr. Weinstein is incorporated by reference. | ||||
| Plantae Bioscience Ltd. | 13D/AActivist | 4.18% | 452.7K | Jul 1, 2026 |
Item 4 of the Schedule 13D is hereby amended and restated as follows: The information contained on the cover pages of this Schedule 13D relating to CHL, CHLP, Plantae and Mr. Weinstein is incorporated by reference. | ||||
| Shayna LP | 13G/APassive | 4.99% | 407.0K | Oct 14, 2025 |
| Carmel Argaman Investments Ltd. | 13G/APassive | 4.99% | 407.0K | Oct 14, 2025 |
| Avraham Levin Holdings Ltd. | 13G/APassive | 4.99% | 407.0K | Oct 14, 2025 |
| Avraham Levin | 13G/APassive | 4.99% | 407.0K | Oct 14, 2025 |
| Chen Franco-Yehuda | 13D/AActivist | 0.51% | 40.1K | Jun 9, 2025 |
"Item 4. Purpose of Transaction" is being amended and restated by this Amendment No. 1 as follows: All of the Issuer's securities directly owned by the Reporting Person was acquired for investment purposes and in consideration for the Reporting Person's services as a former executive officer of the Issuer. In pursuing these purposes, the Reporting Person may further purchase, hold, trade, dispose or otherwise deal in securities of the Issuer. Except as set forth in the previous paragraph, the Reporting Person has no current plans or proposals which relate to or would result in (a) an acquisition by any person of additional securities of the Issuer, or the disposition by any person of securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or of any of its subsidiaries; (d) any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions with may impede the acquisition of control of the Issuer by any person; (h) causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or (j) any action similar to any of those enumerated herein. The Reporting Person may, at any time and from time to time, review or reconsider her position and formulate plans or proposals with respect thereto. | ||||
| Yaky Yanay | 13D/AActivist | 6% | 484.9K | May 20, 2025 |
"Item 4. Purpose of Transaction" is being amended and restated by this Amendment No. 1 as follows: All of the Issuer's securities directly and beneficially owned by the Reporting Person were acquired for investment purposes and in consideration for the Reporting Person's services as an executive officer and Director of the Issuer. In pursuing these purposes, the Reporting Person may further purchase, hold, trade, dispose or otherwise deal in securities of the Issuer. The Reporting Person has no current plans or proposals which relate to or would result in (a) an acquisition by any person of additional securities of the Issuer, or the disposition by any person of securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or of any of its subsidiaries; (d) any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions with may impede the acquisition of control of the Issuer by any person; (h) causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or (j) any action similar to any of those enumerated herein. The Reporting Person may, at any time and from time to time, review or reconsider his position and formulate plans or proposals with respect thereto. | ||||